American Diabetes Association Scientific Sessions
American Diabetes Association Scientific Sessions
October 19, 2016
1 min read

Dapagliflozin, potassium-sparing diuretics lower HbA1c in type 2 diabetes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

NEW ORLEANS — The use of dapagliflozin in combination with potassium-sparing diuretics significantly lowered HbA1c, body weight and systolic blood pressure in patients with type 2 diabetes, according to study results presented at the American Diabetes Association Scientific Sessions.

“The co-administration of dapagliflozin (Farxiga, AstraZeneca) and potassium-sparing agents – including spironolactone – did not produce an increase in potassium levels; and the rate of significant hyperkalemia was numerically lower with dapagliflozin versus placebo in patients treated with potassium-sparing agents at baseline,” Mikhail N. Kosiborod, MD, of Saint Luke’s Health System in Missouri, told Endocrine Today.

Mikhail N. Kosiborod
Mikhail N. Kosiborod

Kosiborod and colleagues analyzed the effects of dapagliflozin at 10 mg (n = 108) versus placebo (n = 119) in patients treated with potassium-sparing diuretics, using pooled data from 14 phase 2b/3 trials over 24 weeks.

The combination lowered HbA1c from baseline by 0.4%, body weight by 2.2 kg and systolic blood pressure by 5.2 mm Hg compared with placebo.

Eight patients administered placebo reported an adverse event of renal impairment or failure compared with four patients who received the dapagliflozin treatment in combination with the potassium-sparing diuretics.

“These findings … provide reassurance to clinicians that there do not appear to be any unexpected safety concerns when SGLT2 inhibitors are administered in patients that are treated with potassium-sparing agents,” Kosiborod said. “These findings are of clinical relevance, since SGLT2 inhibitors and potassium sparing agents are likely to be co-administered in clinical practice – particularly in patients with type 2 diabetes and concomitant hypertension and/or heart failure.” – by Ryan McDonald


Kosiborod MN, et al. 1094-P. Presented at: American Diabetes Association’s Scientific Sessions; June 10-14, 2016; New Orleans.

Disclosure: Kosiborod reports receiving research funding from – and serving as an advisor and consultant to – AstraZeneca and Amgen.